Figure 2.

The β-adrenoceptor antagonist propranolol (2.0 mg/kg) administered subcutaneously 75 min before retention testing blocked the impairing effects induced by the GR agonist RU 28362 (15 ng in 0.5 μl) infused into the hippocampus 60 min before retention testing on probe trial retention performance in a water maze. A, Time spent in the training (T) and opposite (O) quadrants (mean + SEM) in seconds during the 60 sec probe trial. B, Latencies (mean + SEM) in seconds to cross the platform location. C, Representative probe trial swim paths. S indicates start. ^*p < 0.05, ^**p < 0.01 compared with the corresponding vehicle group; ^♦p < 0.05, ^♦♦p < 0.01 compared with the saline-RU 28362 group; ^*p < 0.05, ^**p < 0.01 compared with the training quadrant (n = 13-17 per group).